Table of Contents
Hepatitis Research and Treatment
Volume 2010 (2010), Article ID 495928, 5 pages
http://dx.doi.org/10.1155/2010/495928
Clinical Study

Optimal Erythrocyte Ribavirin Level to Reduce the Risk of Anemia and Obtain an Early Virological Response in Patients with Chronic Hepatitis C Caused by Genotype 1b Infection

1Pharmacy Practice and Sciences, Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
2Research Center for Liver Diseases, The Kitasato Institute Hospital, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8642, Japan
3Department of Internal Medicine, The Kitasato Institute Medical Center Hospital, Kitasato University, 6-100 Arai, Kitamoto-shi, Saitama 364-8501, Japan

Received 13 May 2010; Revised 28 July 2010; Accepted 4 August 2010

Academic Editor: Tatehiro Kagawa

Copyright © 2010 Rie Kubota et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. W. Fried, M. L. Shiffman, K. R. Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. Iino, K. Okita, M. Omata et al., “Clinical efficacy of peg-interferon α-2b and ribabirin combination therapy for 48 weeks in chronic hepatitis C patients with genotype 1 and high viral load.-retrospective comparison with interferon α-2b and ribabirin combination therapy for 24 weeks,” Kan Tan Sui, vol. 49, no. 6, pp. 1099–1121, 2004. View at Google Scholar
  3. P. Glue, “The clinical pharmacology of ribavirin,” Seminars in Liver Disease, vol. 19, no. 1, pp. 17–24, 1999. View at Google Scholar · View at Scopus
  4. J. Y. N. Lau, R. C. Tam, T. J. Liang, and Z. Hong, “Mechanism of action of ribavirin in the combination treatment of chronic HCV infection,” Hepatology, vol. 35, no. 5, pp. 1002–1009, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. L. De Franceschi, G. Fattovich, F. Turrini et al., “Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage,” Hepatology, vol. 31, no. 4, pp. 997–1004, 2000. View at Google Scholar · View at Scopus
  6. H. Hosono, M. Homma, and Y. Inoue, “Effects of ribavirin uptake by red cells via a nucleoside transporter on red cell morphological changes and membrane phospholipids-their relationships with ribavirin induced hemolytic anemia,” Organ Biology, vol. 12, no. 3, p. 256, 2005. View at Google Scholar
  7. M. Homma, A. L. Jayewardene, J. Gambertoglio, and F. Aweeka, “High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 11, pp. 2716–2719, 1999. View at Google Scholar · View at Scopus
  8. Y. Inoue, M. Homma, Y. Matsuzaki et al., “Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy,” Hepatology Research, vol. 34, no. 1, pp. 23–27, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. S. Okuma, “Aging of erythrocytes,” Journal of Practical Pharmacy, vol. 45, no. 10, pp. 59–64, 1994. View at Google Scholar
  10. Y. Takasaki, “Anemia in the elderly,” Internal Medicine, vol. 87, no. 2, pp. 302–306, 2001. View at Google Scholar
  11. H. Nomura, H. Tanimoto, E. Kajiwara et al., “Factors contributing to ribavirin-induced anemia,” Journal of Gastroenterology and Hepatology, vol. 19, no. 11, pp. 1312–1317, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. N. Nakamoto, “Multi-facility joint study of the results of combination therapies for chronic hepatitis C: significance of the measurement of the plasma ribavirin concentration,” Acta Hepatologica Japonica, vol. 45, supplement 1, p. A101, 2004. View at Google Scholar
  13. M. Homma, Y. Matsuzaki, Y. Inoue et al., “Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia,” Clinical Gastroenterology and Hepatology, vol. 2, no. 4, pp. 337–339, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Hiramatsu and N. Hayashi, “PEGIFN-ribavirin combination therapy,” Biomedicine & Therapeutics, vol. 38, no. 9, pp. 991–994, 2004. View at Google Scholar
  15. J. Fellay, A. J. Thompson, D. Ge et al., “ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C,” Nature, vol. 464, no. 7287, pp. 405–408, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus